omalizumab

This page shows the latest omalizumab news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Roche and Novartis’ severe asthma therapy Xolair (omalizumab) has data showing it is effective as a treatment for polyps, but isn’t expected to be approved until the end of next

Latest news

Novartis claims first place for psoriasis drug Cosentyx in China

The firm has recently picked up Chinese approvals for a clutch of therapies including Xolair (omalizumab) for asthma and heart failure therapy Entresto (valsartan/sacubitril).
FDA gives breakthrough status to Xolair for food allergies

The US regulator awarded Xolair (omalizumab) the coveted status for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies, opening up another
AZ prices severe asthma drug Fasenra below competition

Along with Nucala and Cinqair, severe asthma patients can also be treated with Novartis’ older drug Xolair (omalizumab), although that is indicated for allergic asthma and doesn’t specifically address eosinophilic
Novartis adds oral eczema drug with Ziarco acquisition

ZPL389 complements Novartis' existing dermatology medicines, which include Xolair (omalizumab) for chronic idiopathic urticaria (CIU) and recent launch Cosentyx (secukinumab) for psoriasis, as well as pipeline projects including atopic dermatitis
AZ, BMS and Boehringer among UK Prix Galien finalists

Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent allergic asthma.

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest from PMHub

RWE Blog 1: Real-world challenges and real-world data

A meta-analysis of real-world studies where omalizumab treatment of chronic idiopathic urticaria met or improved on both efficacy and safety predictions from the RCTs.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Account Supervisor: Salary TBC

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Medical Writer – Very Flexible Working – Surrey: Negotiable

Account Director: Salary TBC

Graduate Scientific Editor: DOE

Account Executive: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail: We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?: Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Strengthening business competition and reducing anti-competitive practices: How the CMA is tackling high prices for essential drugs...